Journal article · 2020 · Open access

Destabilization of β-catenin and RAS by targeting the Wnt/β-catenin pathway as a potential treatment for triple-negative breast cancer

Won‐Ji Ryu, Jeong Dong Lee, Jong‐Chan Park, Pu-Hyeon Cha, Yong‐Hee Cho, Jee Ye Kim, Joohyuk Sohn, Soonmyung Paik, Kang‐Yell Choi

Experimental & Molecular Medicine, 52(5), 832–842 · Published 1 May 2020 · DOI 10.1038/s12276-020-0440-y

Open PDFView at the publisherCite this paper

In brief

“Destabilization of β-catenin and RAS by targeting the Wnt/β-catenin pathway as a potential treatment for triple-negative breast cancer” is a 2020 journal article by Won‐Ji Ryu and 8 co-authors, published in Experimental & Molecular Medicine. OpenAlex counts 43 citations as of 21 November 2026, which puts it in the top 6% of works published in 2020 by citations. It is open access under a CC BY licence: the full text is free to read at Experimental & Molecular Medicine.

Citations
43
Most cited in
2026 (9)
Field-weighted impact
1.35
References
32
Authors
9

Abstract

Triple-negative breast cancer (TNBC) is a severe and heterogeneous disease that lacks an approved targeted therapy and has a poor clinical outcome to chemotherapy. Although the RAS-ERK signaling axis is rarely mutated in TNBC, ~50% of TNBCs show an increased copy number and overexpression of epidermal growth factor receptor (EGFR). However, EGFR-targeted therapies have offered no improvement in patient survival, underscoring the need to explore downstream targets, including RAS. We found that both β-catenin and RAS, as well as epidermal growth factor receptor (EGFR), are overexpressed and correlated with one another in tumor tissues of TNBC patients. KYA1797K, an Axin-binding small molecule reducing β-catenin and RAS expression via degradation and suppressing EGFR expression via transcriptional repression, inhibited the proliferation and the metastatic capability of stable cell lines as well as patient-derived cells (PDCs) established from TNBC patient tissues. KYA1797K also suppressed the stemness of 3D-cultured PDCs and xenografted tumors established by using residual tumors from TNBC patients and those established by the TNBC cell line. Targeting both the Wnt/β-catenin and RAS-ERK pathways via small molecules simultaneously reducing the levels of β-catenin, RAS, and EGFR could be a potential therapeutic approach for TNBC.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Ryu, W., Lee, J. D., Park, J., Cha, P.-H., Cho, Y., Kim, J. Y., Sohn, J., Paik, S., & Choi, K. (2020). Destabilization of β-catenin and RAS by targeting the Wnt/β-catenin pathway as a potential treatment for triple-negative breast cancer. Experimental & Molecular Medicine, 52(5), 832–842. https://doi.org/10.1038/s12276-020-0440-y

MLA 9

Ryu, Won‐Ji, et al. “Destabilization of β-catenin and RAS by targeting the Wnt/β-catenin pathway as a potential treatment for triple-negative breast cancer.” Experimental & Molecular Medicine, vol. 52, no. 5, 2020, pp. 832–842. https://doi.org/10.1038/s12276-020-0440-y.

Chicago

Ryu, Won‐Ji, Jeong Dong Lee, Jong‐Chan Park, Pu-Hyeon Cha, Yong‐Hee Cho, Jee Ye Kim, Joohyuk Sohn, Soonmyung Paik, and Kang‐Yell Choi. 2020. “Destabilization of β-catenin and RAS by targeting the Wnt/β-catenin pathway as a potential treatment for triple-negative breast cancer.” Experimental & Molecular Medicine 52 (5): 832–842. https://doi.org/10.1038/s12276-020-0440-y.

Harvard

Ryu, W. et al. (2020) ‘Destabilization of β-catenin and RAS by targeting the Wnt/β-catenin pathway as a potential treatment for triple-negative breast cancer’, Experimental & Molecular Medicine, 52(5), pp. 832–842. doi:10.1038/s12276-020-0440-y.

IEEE

W. Ryu et al., “Destabilization of β-catenin and RAS by targeting the Wnt/β-catenin pathway as a potential treatment for triple-negative breast cancer,” Experimental & Molecular Medicine, vol. 52, no. 5, pp. 832–842, 2020, doi: 10.1038/s12276-020-0440-y.

BibTeX

@article{ryu2020destabilization,
  title     = {{Destabilization of β-catenin and RAS by targeting the Wnt/β-catenin pathway as a potential treatment for triple-negative breast cancer}},
  author    = {Ryu, Won‐Ji and Lee, Jeong Dong and Park, Jong‐Chan and Cha, Pu-Hyeon and Cho, Yong‐Hee and Kim, Jee Ye and Sohn, Joohyuk and Paik, Soonmyung and Choi, Kang‐Yell},
  journal   = {Experimental \& Molecular Medicine},
  year      = {2020},
  volume    = {52},
  number    = {5},
  pages     = {832--842},
  doi       = {10.1038/s12276-020-0440-y},
  url       = {https://doi.org/10.1038/s12276-020-0440-y}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
202033
202166
202266
202366
202477
202566
202699

Its field-weighted citation impact is 1.35: it has been cited 1.35 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Wnt/β-catenin signaling in development and cancer

  • triple-negative breast cancer
  • Wnt/β-catenin signaling
  • Ras/ERK pathway
  • β-catenin stabilization
  • Ras
  • EGFR
  • protein degradation
  • cancer stemness

Work with this paper

Most-cited papers in Biochemistry, Genetics and Molecular Biology

All highly cited Biochemistry, Genetics and Molecular Biology papers

Questions about this paper

How do I cite this paper in APA style?

Ryu, W., Lee, J. D., Park, J., Cha, P.-H., Cho, Y., Kim, J. Y., Sohn, J., Paik, S., & Choi, K. (2020). Destabilization of β-catenin and RAS by targeting the Wnt/β-catenin pathway as a potential treatment for triple-negative breast cancer. Experimental & Molecular Medicine, 52(5), 832–842. https://doi.org/10.1038/s12276-020-0440-y

How many times has this paper been cited?

43 times, according to OpenAlex on 21 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Experimental & Molecular Medicine: sign in and open the PDF from this page.

Who wrote this paper?

Won‐Ji Ryu, Jeong Dong Lee, Jong‐Chan Park, Pu-Hyeon Cha, Yong‐Hee Cho, Jee Ye Kim, Joohyuk Sohn, Soonmyung Paik, Kang‐Yell Choi.

What is the DOI of this paper?

10.1038/s12276-020-0440-y, permanently at https://doi.org/10.1038/s12276-020-0440-y. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 21 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.